AstraZeneca PLC Hunting More Deals Like Amgen Tie-up

AstraZeneca is seeking more deals to fill its sparse drug pipeline like the one just signed with Amgen, but is not in the market for the kind of large acquisition some investors have speculated about. Martin Mackay, head of research at Britain's second-biggest drugmaker, said he was considering smaller acquisitions, product licensing deals and more partnerships with industry peers. The deal with Amgen buys rights to jointly develop and sell five of the U.S. biotech firm's experimental autoimmune, inflammatory and respiratory drugs, and follows a similar tie-up in diabetes five years ago with Bristol-Myers Squibb.

Back to news